Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival - PubMed (original) (raw)

Comparative Study

. 2001 Jan 16;98(2):513-8.

doi: 10.1073/pnas.98.2.513. Epub 2001 Jan 9.

Affiliations

Comparative Study

Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival

M F Princiotta et al. Proc Natl Acad Sci U S A. 2001.

Abstract

The proteasome is the primary protease used by cells for degrading proteins and generating peptide ligands for class I molecules of the major histocompatibility complex. Based on the properties of cells adapted to grow in the presence of the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone (NLVS), it was proposed that proteasomes can be replaced by alternative proteolytic systems, particularly a large proteolytic complex with a tripeptidyl peptidase II activity. Here we show that NLVS-adapted cells retain sensitivity to a number of highly specific proteasome inhibitors with regard to antigenic peptide generation, accumulation of polyubiquitinated proteins, degradation of p53, and cell viability. In addition, we show that in the same assays (with a single minor exception), NLVS-adapted cells are about as sensitive as nonselected cells to Ala-Ala-Phe-chloromethylketone, a specific inhibitor of tripeptidyl peptidase II activity. Based on these findings, we conclude that proteasomes still have essential proteolytic functions in adapted cells that are not replaced by Ala-Ala-Phe-chloromethylketone-sensitive proteases.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Effect of proteasome inhibitors on antigen processing in EL4 and EL4ad cells. Cells were treated with proteasome inhibitors and then infected with PR8 influenza virus. TCD8+ cells specific for influenza NP366–374 were added 1 h after infection. Brefeldin A was added 5 h after infection. After an additional 4 h, cells were harvested, stained for CD8 and intracellular IFN-γ, and analyzed by cytofluorography. (A) The percentage of CD8+ cells positive for intracellular IFN-γ is represented graphically. (B) To ensure that proteasome inhibitors were not inhibiting IFN-γ production in TCD8+ cells, the assay described in A was performed with the use of EL4 cells titrated with limiting quantities of NP366–374 peptide as antigen-presenting cells and TCD8+ cells exposed to the same inhibitor concentrations as in A. Legend symbols are defined in A.

Figure 2

Figure 2

Effect of proteasome inhibitors on the accumulation of polyUb proteins in EL4 and EL4ad cells. (A and_B_) EL4 (A) and EL4ad (B) cells treated with inhibitors for 2, 4, and 8 h were analyzed by Western blotting with the use of the FK2 mAb, the binding of which was visualized by chemiluminescence. The inhibitors used were 10 μM lactacystin (LC), 10 μM zLLL (zLLL), 10 μM AAF-cmk (AAF), no inhibitor (NI), 50 μM NLVS (NLVS), and 1 μM epoxomicin (Epox). (C) The increase in FK2 staining was quantitated and is represented graphically.

Figure 3

Figure 3

Effect of proteasome inhibitors on the accumulation of p53 in EL4 and EL4ad cells. Aliquots from cells analyzed in Fig. 2 were Western blotted with the use of polyclonal p53-specific antibodies. The inhibitors used were 10 μM lactacystin (LC), 10 μM zLLL (zLLL), 10 μM AAF-cmk (AAF), 1 μM epoxomicin (Epox), 1 μM boro-LLL (Boro), 1 μM PS-341 (PS-341), and no inhibitor (NI). (A) Antibody binding was visualized by chemiluminescence. (B) The increase in p53 staining was quantitated and is represented graphically.

Figure 4

Figure 4

Effect of AAF-cmk on AAF-amc hydrolysis in EL4ad cells. EL4ad cells were treated with 10 μM AAF-cmk or 10 μM lactacystin for 90 min at 37°C and then incubated with 100 μM AAF-amc. Hydrolysis of AAF-amc was determined by measuring fluorescence at 5–10-min intervals.

Similar articles

Cited by

References

    1. Baumeister W, Walz J, Zuhl F, Seemuller E. Cell. 1998;92:367–380. - PubMed
    1. DeMartino G N, Slaughter C A. J Biol Chem. 1999;274:22123–22126. - PubMed
    1. Deveraux Q, Ustrell V, Pickart C, Rechsteiner M. J Biol Chem. 1994;269:7059–7061. - PubMed
    1. Yewdell J W, Antón L C, Bennink J R. J Immunol. 1996;157:1823–1826. - PubMed
    1. Rock K L, Goldberg A L. Annu Rev Immunol. 1999;17:739–779. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources